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Abstract
Background: Pancreatic adenocarcinoma (PAC) is one of the most intractable malignancies. In order to search for potential
new therapeutic targets, we relied on computational methods aimed at identifying transcription factor binding sites (TFBSs)
over-represented in the promoter regions of genes differentially expressed in PAC. Though many computational methods
have been implemented to accomplish this, none has gained overall acceptance or produced proven novel targets in PAC.
To this end we have developed DEMON, a novel method for motif detection.
Methodology: DEMON relies on a hidden Markov model to score the appearance of sequence motifs, taking into account all
potential sites in a promoter of potentially varying binding affinities. We demonstrate DEMON’s accuracy on simulated and
real data sets. Applying DEMON to PAC-related data sets identifies the RUNX family as highly enriched in PAC-related genes.
Using a novel experimental paradigm to distinguish between normal and PAC cells, we find that RUNX3 mRNA (but not
RUNX1 or RUNX2 mRNAs) exhibits time-dependent increases in normal but not in PAC cells. These increases are
accompanied by changes in mRNA levels of putative RUNX gene targets.
Conclusions: The integrated application of DEMON and a novel differentiation system led to the identification of a single
family member, RUNX3, which together with four of its putative targets showed a robust response to a differentiation
stimulus in healthy cells, whereas this regulatory mechanism was absent in PAC cells, emphasizing RUNX3 as a promising
target for further studies.
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Introduction
Pancreatic adenocarcinoma (PAC) is one of the most aggressive
cancers. Although 10th in incidence, it is the fourth leading cause
of cancer deaths in the Western world. PAC is characterized by
late diagnosis, rapid progression and extensive metastasis and is
almost completely refractory to all therapeutic regimens. Although
10–15% of PAC tumors can be treated by partial pancreatectomy,
the mean time between diagnosis and death is 3–6 months and the
5 year survival rate is under 5%. In the US, approximately 30,000
new cases are diagnosed each year and virtually the same number
of PAC patients die each year of the disease[1,2]. This grim
picture makes this cancer a worthy subject for searching for novel
therapeutic targets. However, published gene expression studies,
so far, have failed to identify useful therapeutic targets.
Identification of transcription factors (TFs) involved in key
biological processes and various pathological conditions, particu-
larly cancer and inherited disorders, has gained popularity in
recent years. TFs are master controllers of changes in expression of
multiple genes and thus may serve as preferred targets for
therapies of human diseases. A relatively large number of methods
for identifying enriched TF binding sites (TFBSs) exist [3–5] but
no single method has gained universal preference over the others.
Application of the state-of-the-art PRIMA algorithm [4] to data
sets reflecting differential expression of genes in PAC pointed to
ZNF350 as an important TF in PAC biology (unpublished).
However, qRT-PCR experiments showed only modest changes in
ZNF350 expression upon serum removal of PAC cells (see Fig. S1).
In view of the importance of this methodology, we sought to
develop a novel method aimed at achieving better predictive value
in biological experiments.
A relatively large number of PAC gene expression studies have
been performed, using both healthy and diseased pancreatic
tissues and PAC lines in vitro. Brandt et al. [6] reviewed data from
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expression of which change in PAC; 148 of these genes were
identified in two or more studies. The list compiled by Brandt et al.
includes genes that are expressed in a high proportion of PAC
studies and had been associated with many types of cancers, such
as Ras, Ink4, P53, etc. None, however, appear to explain the
‘‘catastrophic’’ [7] progression of this disease. Although individual
proteins may serve as promising targets for drug development, the
search for therapeutic targets in PAC has failed, so far, to produce
novel promising drug leads. Conceptually, therapies targeted at
TFs that are master regulators of expression of a large number of
genes, are potentially more likely to affect cancer cell biology and
are particularly attractive.
Here we have applied a new method, DEMON, for detecting
enriched TFBSs and a new paradigm for comparing normal
pancreatic and PAC cells. Applying DEMON to a PAC
experimental data set predicted that binding sites for the RUNX
subfamily of TFs are highly enriched in the pertinent differentially
expressed gene sets. qRT-PCR confirmed RUNX3 as a
differentially expressed TF. In conclusion, DEMON proved to
be a helpful predictive tool in TFBSs analysis and, together with
experimental results, suggests that RUNX3 may prove to be an
important target TF in pancreatic cancer research.
Results
Detecting Enriched MOtifs in co-regulated geNes
(DEMON)
Given a target set of promoters of co-regulated genes and a set of
known TFBS motifs (represented asposition weight matrices from the
TRANSFAC database [8], see Methods), DEMON seeks motifs that
appear in those promoters more frequently than expected by chance
(i.e., motifsthatareenriched inthetargetset).The algorithmutilizes a
hidden Markov model (HMM) to describe the probabilistic process
that generates the promoter sequences, and to estimate how likely it is
that any given motif is enriched in the target set.
Each HMM contains states for a unique motif, and background
states that model inter-motif segments (Fig. 1). DEMON scores
each promoter for the appearance of any given motif. This score
reflects the probability that the sequence was generated based on
the HMM describing the motif, vs. the probability that it was
generated based on a simple background model. Given a target set
of co-regulated genes, the scores of the promoters are summed up
for each HMM, and compared to sums of scores obtained with
random target sets. This comparison is used to assign a p-value for
each motif that reflects its abundance in the promoter regions of
the target set (see Fig. 2 and Methods).
Figure 1. The structure of DEMON’s HMM. The HMM is comprised of motif states (in pink), background states (in blue) and a start state. A
background state is defined for each nucleotide (four states), and a motif state is defined for every position along the PWM corresponding to the
TFBS of interest. The emission probabilities of the motif states are defined according to the PWM, and those of the background states are set to 1 for
the corresponding nucleotide. Transition probabilities between the background states reflect the distribution of dinucleotides across all putative
promoter regions in human. The transition probability from each motif state to the next is set to 1. Remaining transitions include moving to the
background states (dashed arrows) or moving to the first motif state (solid arrows). These transitions are learned using the Baum-Welch algorithm.
doi:10.1371/journal.pone.0014423.g001
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To test our approach, we first benchmarked DEMON on
simulated data. To this end we simulated sets of 100 random
promoters, whose sequences were selected according to the
background probability of dinucleotides in real promoter regions
(Methods). We then planted a real motif in x% (10#x#90) of the
promoters in each set (three instances of the motifs were planted in
each promoter). We repeated this procedure for all the vertebrate
position weight matrices (PWMs) in the TRANSFAC database [8]
(see Methods).
Figure 3 compares the performance of DEMON to that of the
PRIMA algorithm. We chose PRIMA as a representative of a
group of methods that use a hard threshold to identify putative
appearances of motifs in any given promoter. Such methods may
fail to identify ‘‘weak’’ occurrences of the motif and often do not
take into account the actual number of occurrences of the motif
(for instance, in PRIMA, promoters are categorized to those
having 0, 1, 2, or more than 2 occurrences of the motif).
Evidently, in all cases DEMON achieves better results both in
terms of specificity and sensitivity. We conducted additional
simulations, varying the number of promoters in each set, or the
number of planted motifs in each promoter. The results remained
qualitatively similar (Figs S2 and S3).
Prima has a marginal advantage over DEMON on small data
sets (for 30 promoters, DEMON false positive rate (FPR) is 0.0006
versus 0.0004 for PRIMA, see Fig. S3). However, these very low
numbers make the FPR of both methods essentially equal.
Next, we compared the two methods on the recently published
Amadeus metazoan benchmark, which is a collection of TF and
microRNA target gene sets derived from high-throughput
Figure 2. Schematic of the DEMON’s algorithm work flow. a. Retrieving a list of co-expressed genes from high-throughput experiments. b. For
each HMM-promoter pair a score is computed as the ratio between the probability to emit the promoter sequence using the TFBS HMM and the
probability to emit the promoter sequence using a background HMM. The sum of scores for each TF is used for computing a single score reflecting
the TF’s overall abundance in the input promoter set. c. Randomly selecting 100 promoter data sets with the same size as the original data set. Scores
are calculated as before for those data sets. d. Each TF is assigned with an empirical p-value defined as the percentage of random cases in which it
scored higher.
doi:10.1371/journal.pone.0014423.g002
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experiments) [9]. We downloaded all human and mouse entries
of this collection, where each entry contains a single TF and a list
of target genes (ranging from 25 to 2238 genes).
Table 1 presents the results of DEMON and PRIMA over all
the examined data entries. DEMON identified the true TF in
70.3% of the cases (where in 51.8% of the cases the true TF is
ranked in first or second place) while PRIMA identified it in
55.5% of the cases (in 48.1% of the cases, the true TF is ranked in
first or second place). Moreover, in 37% of the cases DEMON
ranked the correct TF higher than PRIMA whereas PRIMA
ranked the right TF higher than DEMON in only 18.5% of the
cases.
Detecting TFs involved in the transcriptional regulation
in PAC
We initially used a list of differentially expressed genes in PAC
compiled by Brandt et al. [6] from 10 studies. We obtained from
that list a smaller list of 45 genes that were identified as
differentially expressed in 3 or more studies, of which 38 (30 that
exhibited increased and 8 that exhibited decreased expression)
matched our collection of human promoters (see Table S1). We
analyzed this list using DEMON and found significant enrichment
of 6 motifs, of which the most highly enriched motifs were for the
RUNX sub-family of TFs (also called the AML sub-family). When
we limited the consensus data set to the 30 genes that exhibited
increased transcription, DEMON found significant enrichment of
8 motifs, of which the most highly enriched motifs were also for
RUNX.
The TFs of the RUNX sub-family, are binding partners of
heterodimeric transcriptional regulators denoted as CBFs (core-
binding factors) of which the CBFa (RUNX) members bind
directly to DNA and the two alternatively-spliced CBFb (also
known as PEBP) members bind to the CBFa subunit and enhance
its DNA binding [10]. It is noteworthy that PEBP appears as a
third and a second most enriched TF, respectively (see Table 2).
We used PRIMA to analyze the same lists, and found a
significant enrichment of one motif, ZBRK1, also called ZNF350
(see Table S2). However, qRT-PCR experiments showed only
modest changes in ZNF350 expression in PANC-1s upon serum
withdrawal (unpublished results, see Fig. S1).
The three highly homologous human RUNX TFs (RUNX1, 2,
and 3) have been implicated in developmental processes and,
notably, in cancer. RUNX1 (also known as AML1) has been
extensively documented as an important factor in hematopoiesis
and in the etiology of acute myelogenous leukemia (for review see
[11]). RUNX2 has been shown to be involved in bone
development (for review see [12]) and RUNX3 was documented
as an important TF in development of T-lymphocytes [13–15] and
has been associated with the pathogenesis of several malignancies
[16], including PAC [17,18]. Hence, the DEMON analysis
predicts that RUNX TF family members are top candidates
responsible for altered transcription of genes in the PAC consensus
data set.
RUNX experimental validation
Most of the experimental data in cancer compare gene
expression of cancer tissues with that of healthy tissues of human
donors. This comparison filters out the variability of gene
expression due to sex and age of the patient, stage of the disease,
involvement of unrelated pathological conditions, different
(cancer-targeted and other) drug therapies, as well as ethnic
genetics and lifestyles. Thus, only the genes common to PAC on
the background of all the above sources of variability are
represented. It is noteworthy that Brandt’s et al. [6] list of close
to one thousand differentially expressed genes shrinks to 148 and
45 when one adds a requirement that it must appear in at least two
or three studies, respectively.
Figure 3. Results from the simulation benchmark. A comparison between DEMON’s and PRIMA’s performance on data sets with various
percentage of promoters with planted motifs.
doi:10.1371/journal.pone.0014423.g003
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differential gene expression patterns observed in two cell types in
culture: hIPCs, pancreatic precursor cells that outgrow from
cultured human islets of Langerhans of healthy cadaveric donors,
and PANC-1 cells, an established line of human PAC. Impor-
tantly, both types of cells undergo mesenchymal-to-epithelial
transition (MET) and partially differentiate to a neuroendocrine
phenotype when allowed to aggregate in serum-free medium
[19,20]. While hIPCs cease to proliferate and some of them die,
PANC-1 cells continue to proliferate under these conditions.
The primary assumption of our paradigm is that the response to
a differentiation stimulus will reveal changes of gene expression
that distinguish normal from PAC cells. To the best of our
knowledge, there is no proof in the literature that comparing
processes in normal and cancer cells of similar origin under
conditions that induce partial differentiation will yield insight into
cancer-related gene expression. Continuous proliferation of cells in
serum-free medium could be attributed to mutations of key genes
(e.g., K-Ras). However, not all cancer cell traits (e.g. migration,
invasiveness, stimulation of angiogenesis, resistance to cytotoxic
agents) can be directly related to their ability to proliferate in the
absence of growth factors. It is possible that this paradigm will
yield genes that were missed in the traditional healthy vs. diseased
tissue methods. We have, therefore, cultured both hIPCs and
PANC-1 cells in serum-free medium for 24 h and compared
changes in gene expression in both cell types. This comparison
yielded a manually-curated set of 30 genes, whose expression
changed significantly in one cell type and either did not change or
exhibited change in the opposite direction in the other (see Table
S3). We analyzed this set with DEMON (see Table S4). Although
PEBP (CBFb) was only marginally enriched (p,0.1) in this list, it
appeared among the ten top TFBSs exhibiting the lowest p-values
both in the lists derived by DEMON from consensus data sets
(ranked 2nd and 3rd) and from the hIPCs vs. PANC-1 cells
experiment data set (ranked 6th). This finding supported the
prediction that RUNX sub-family members may be involved in
PAC. Analysis of the same data set with PRIMA did not find any
enriched motifs (see Table S5).
To obtain experimental evidence for RUNX distinguishing
between normal and PAC cells, we monitored expression of
RUNX1, 2 and 3 mRNAs by qRT-PCR as a function of time of
serum deprivation of hIPCs and PANC-1 cells (Fig. 4). There was
little change in the expression of RUNX1 and 2 transcripts in
either cell type. The expression of RUNX3, however, was
markedly increased in a time-dependent manner in hIPCs while
there was virtually no change in PANC-1 cells. It appears,
therefore, that the expression of RUNX3 is regulated in hIPCs
during differentiation but fails to respond to the differentiation
stimulus in PANC-1 cells.
To further validate this finding, we assayed in hIPCs the
expression of five putative RUNX targets, ECM2, DUSP2,
ESAM, PECAM, and ITGB4, that were chosen from a list of
putative RUNX targets generated based on a procedure similar to
the method described in [4]. Four of these mRNAs exhibited
marked changes in expression (see Fig. 5A), while the fifth, ITGB4,
exhibited only a transient two-fold increase. By comparison, the
expression of these genes did not change in PANC-1 cells (see
Fig. 5B). When the expression of the same genes was examined on
the microarray data, none (including RUNX3) were high enough
for meaningful analysis, confirming the superior sensitivity of
qRT-PCR.
Table 2. Top 10 TFBSs that were found by DEMON in the
consensus data set and in the 30 consensus genes that
exhibited increased transcription.
Consensus data
set (38 genes)
Consensus data
set (30 genes)
TFBS P-value TFBS P-value
AML 0.00004 AML 0.000005
CP2 0.00019 PEBP 0.00008
PEBP 0.00025 PAX6 0.00028
PAX6 0.00035 CACCCBF 0.00038
MAZR 0.0008 CP2/LBP1C/LSF 0.00059
CACCCBF 0.0011 MAZR 0.0014
NFY 0.0026 PAX 0.0014
AHR 0.0028 LFA1 0.0016
LFA1 0.0059 AHR 0.0042
PAX 0.0061 NFY 0.0055
Enriched TFBSs that pass a 0.05 FDR threshold appear in bold.
doi:10.1371/journal.pone.0014423.t002
Table 1. DEMON and PRIMA results on the Amadeus
metazoan benchmark.
Organism TF # of genes
DEMON’s
rank
PRIMA’s
rank
Human CREB 2334 1 2
E2F4 201 2 3
E2F4 79 2 1
ER 495 16 –
ETS1 1189 5 10
E2F 264 1 1
NF-Y 343 1 1
HNF1a 206 1 1
HNF4a 1471 14 –
HNF6 211 1 –
HSF1 328 – 1
IRF/NF-kB 563 2 1
Nanog 710 – –
NF- kB 270 – 1
Nrf1 672 1 1
OCT4 239 1 2
p53 38 – –
SOX2 537 – –
SRF 172 1 1
YY1 708 4 1
Mouse FOXP3 1053 – –
IRF/NF-kB3 2 2 1 1
MEF2 25 2 –
MyoD 102 2 –
MyoD 102 – –
MyoG 106 – –
MyoG 78 (MyoD) – –
The higher rank for each TF is marked in bold.
doi:10.1371/journal.pone.0014423.t001
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We have presented a new algorithm for detecting enriched
TFBSs in a given set of promoters. The algorithm uses an HMM-
based score to take into account all possible parses of a promoter
sequence into binding sites and background nucleotides. It weighs
in a principled manner all the potential binding sites along the
promoter, making it possible to consider multiple weak binding
sites that would not have passed a significance threshold. This is
the first use of such a method for enrichment tests. We show that it
outperforms a previous approach (PRIMA) to the problem, which
uses a threshold to make binary decisions on actual binding sites.
Three aspects of the experimental results presented in this
report appear to be of major importance. First, they experimen-
tally validate the power of the DEMON analysis to predict TFs
(and their target genes) from a small number of differentially
expressed genes in PAC. Although DEMON proved to be superior
to PRIMA in simulation experiments, its value can be proven only
by its experimental predictive ability. In our case, the power of
DEMON was not only validated for RUNX3, but also by the
intrinsically consistent identification of CBFb, the heterodimeric
partner(s) of the RUNX sub-family.
Second, our results strongly suggest that RUNX3 and its
heterodimeric partner CBFb should be further investigated
Figure 4. Kinetics of changes in expression of RUNX genes. hIPCs and PANC-1 cells were either cultured in serum-containing medium (t=0) or
for the indicated times in serum-free medium. RNA was extracted and qRT-PCR performed as described in Materials and Methods. Results are
presented as % change in mRNA levels of the three RUNX genes as a function of time in serum-free medium.
doi:10.1371/journal.pone.0014423.g004
Figure 5. Kinetics of changes in expression of RUNX-controlled genes. A. hIPCs and B. PANC-1 cells were either cultured in serum-containing
medium (t=0) or for the indicated times in serum-free medium. RNA was extracted and qRT-PCR performed as described in Materials and Methods.
Results are presented as % change in mRNA levels of the indicated genes as a function of time in serum-free medium.
doi:10.1371/journal.pone.0014423.g005
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expression of RUNX1 were identified in a significant proportion
of leukemias [11]. RUNX2 and 3 genes have been extensively
studied as developmental TFs. RUNX2 was shown to be crucial
for bone and skeletal development [12]. RUNX3 was shown to be
directly involved in the commitment of CD4+/CD8+ cells into
CD8+ T-cells and in the maturation of dendritic T-cells [15,21].
Some reports demonstrate the role of RUNX3 in the development
of the sensory neuronal system [22,23]. Hypermethylation of the
RUNX3 promoter region has been correlated with various
metastatic malignancies, such as breast, non-small cell lung,
gastric, pancreatic, colorectal, or hepatocellular carcinomas [24].
Importantly, restoration of RUNX3 expression in cancer cell lines
leads to apoptosis or decreased proliferation of cancer cells and to
their differentiation [25–28]. These, and similar reports, estab-
lished that RUNX3 appears to function as a tumor suppressor.
They are further confirmed by our finding that untransformed
mesenchymal hIPCs respond to a differentiation stimulus by
increased RUNX3 transcription and proliferation arrest, while
malignant PANC-1 cells appear to have lost this regulatory
response and continue to proliferate. In human PAC, hyper-
methylation and loss of heterozygosity of RUNX3 were found in a
large proportion of PAC tissues and correlated with worse
prognosis [17,18]. These findings place RUNX3 as another
PAC-associated gene product. DEMON analysis, however, places
RUNX and its partner, PEBP, as putatively very important TFs
controlling the expression of many PAC-related genes.
Third, our results confirm the hypothesis that the differences
between normal pancreatic and PAC cells are revealed following a
differentiation stimulus. This assumption is further strengthened by
a recent analysis of transcriptomes involved in cancer and
development [29]. In proliferating hIPCs and PANC-1 cells, both
exhibiting mesenchymal phenotypes [19], few RUNX3 transcripts
are present (thresholds of 31.5 and 30 cycles, respectively). By 24 h
in differentiation medium, however, the levels of RUNX3 mRNAs
in hIPCs increased more than 1000-fold whereas there was virtually
no response in PANC-1 cells. Likewise, putative RUNX3 target
genes exhibited altered transcription in hIPCs but no changes in
PANC-1 cells. Importantly, Li et al. [30] have found that RUNX3 is
expressed only in islets and a proportion of PAC tissues. Our
experimental data demonstrate that while RUNX3 mRNA
expression may not be different in proliferating normal and PAC
cells, its role is revealed only following differentiation stimulus, thus
explainingtheapparent disagreementbetween the findingsofWada
et al. and Nomoto et al. [17,18] and those of Li et al. [30].
Importantly, the differentiation-induced response of RUNX3
and its five putative targets in hIPCs cannot be gleaned from
microarray analysis due to the absence of signal or their very low
levels. Although PECAM1 and CBFA2T1 signals increased more
than two-fold, their signals were too low to be significant. This
justifies the use of computational methods, such as DEMON or
PRIMA, to identify gene targets and their validation by the more
sensitive qRT-PCR technique. Admittedly, qRT-PCR cannot
reveal epigenetically-controlled regulations of cell phenotype.
Our results suggest loss of response of the RUNX3 gene in PAC
and suggest further studies, such as investigation of methylation of
its promoter, and a more extensive expression study of putative
RUNX target genes.
Materials and Methods
The DEMON Algorithm
The DEMON algorithm uses HMMs for representing TFBSs.
Each HMM is comprised of two types of states: motif states and
background states (Fig. 1). A background state is defined for each
nucleotide (four states), and a motif state is defined for every
position along the PWM corresponding to the TFBS of interest.
The emission probabilities of the motif states are defined according
to the PWM, and those of the background states are set to 1 for the
corresponding nucleotide. Transition probabilities between the
background states reflect the distribution of dinucleotides across all
putative promoter regions in human. The transition probability
from each motif state to the next is set to 1. Remaining transitions
include moving to the background states (Fig. 1, dashed arrows) or
moving to the first motif state (Fig. 1, solid arrows). These
transitions are learned using the Baum-Welch algorithm [31]
(Supporting Information S1).
The inputs to DEMON are the list of genes of interest (Fig. 2a)
and a set of TFBS motifs represented by PWMs. The output is a
list of TFs whose binding sites are statistically over-represented in
the promoter regions of the given list of genes.
As a first step, we build an HMM from every given PWM, and
each HMM-promoter pair is assigned with a score reflecting the
likelihood that the respective TFBS appears in the respective
promoter region. This score is computed as the ratio between two
values (Fig. 2b): (i) the probability to emit the promoter sequence
using the TFBS HMM in Figure 1, and (ii) the probability to emit
the promoter sequence using an HMM comprised solely of the
background states. The probability values are computed using the
Forward algorithm [32]. The pairwise scores are then being used
for computing a single score for each TF, reflecting its overall
abundance in the input promoter set. This score is defined as the
sum over all scores assigned individually with each promoter.
In the second step, we use an empirical approach for evaluating
the statistical significance of the overall likelihood scores computed
for the TFs. We randomly select a similar number of promoters as
in the original data set from the pool of all human promoter
regions and compute a new score for each TF as before (Fig. 2c).
We repeat this procedure 100 times, ending up with an empirical
distribution of random likelihood scores. Each TF is then assigned
with an empirical p-value defines as the probability to see the
target set sum of scores, given the random sums which are
assumed to be normally distributed (Fig. 2d). i.e., we compute the
average and standard deviation of the random scores, and use the
normal cumulative distribution function to compute the probabil-
ity that an observation from a standard normal distribution will be
higher than the target set sum of scores. The p-values are
corrected for multiple hypotheses testing using the false discovery
rate procedure [33]. We report all findings with false discovery
rate under 5%.
Data Acquisition and PRIMA implementation
We obtained a set of nucleotide distribution matrices that model
vertebrate TFBSs from the TRANSFAC database (release 11.1)
[8]. A total of 588 vertebrate matrices were downloaded from the
database. The matrices were transformed to probability matrices
that delineate the probability of each nucleotide to appear in each
position in the TFBS. Since the database is redundant and some of
the matrices describe similar TFBS, we clustered the matrices in a
preprocessing step in a procedure similar to that used in [4]. To
this end, we built a PWM w from each probability matrix m, and
used a low pre-calculated threshold t to scan the human genome
promoters. The threshold is computed using two sets of
background promoters: (i) random promoters that are built based
on the nucleotide distribution in all the promoters, (ii) randomly
chosen segments of real promoters. The two sets are scanned by
each PWM w and the threshold t is defined as the maximum
between the 100
th highest score from each of the two background
RUNX3 in Pancreatic Cancer
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had a similarity score to the PWM w above the threshold t was
marked as a putative instance of w. Then, each pair of matrices
that x% of their appearances on the promoter set were overlapping
was clustered and the matrix with the lower information content
(i.e., the matrix which is less different from a uniform distribution)
was removed. As the value of x grows, the clustering criterion
becomes more stringent and the resulted matrices set grows, and
vice versa. We used x=0.2 to obtain a set of 219 matrices to use in
our analysis.
We downloaded the complete set of human promoters from the
UCSC Genome Browser database [34,35]. Based on preliminary
testing and recent studies claiming that most of the TFBSs in
human promoters are located near the transcription start site [36],
we define the promoter regions of the genes as the 500 bp
sequence upstream to the transcription start site.
We have implemented PRIMA as described in [4].
Cell cultures
Human islet-derived pancreatic precursor cells (hIPCs) were
isolated and propagated in modified CMRL medium as previously
described [20]. Human pancreatic adenocarcinoma cell line
PANC-1 was purchased from American Tissue Type Collection
and maintained in Dulbecco-modified minimal Eagle’s Medium
(DMEM) as previously described [20]. Partial differentiation of
either cell type was achieved by culturing cells in serum-free
medium, essentially as described previously [20]. Cells were grown
and maintained in 95:5% air:CO2 atmosphere at 37u.
DNA Microarrays
Affymetrix GeneChip Human Genome U133 Plus 2.0 from
microarray (catalog # 900466) was used, yielding 12,760
sequences. hIPCs were assayed in triplicate, each of a separate
biological sample. PANC-1 cells were assayed in pentaplicate
arrays, two from separate biological replicates and another
biological replicate run in triplicate arrays. Each set was comprised
of samples isolated from proliferating cells (t=0, in 10% fetal
bovine serum-containing medium) and cells after 24 h in serum-
free (differentiation) medium. RNA samples were isolated and
processed according to microarray manufacturer’s instructions.
The analysis, including normalization, was carried out using
Affymetrix proprietary software.
Genes, whose expression changed at least two-fold upon 24 h in
serum-free medium in either cell type, were compared. The
selected set included genes that either exhibited changes in a single
cell type, or genes that exhibited changes in the opposite direction.
This set was subsequently used for DEMON analysis (Table S4).
Quantitative real-time polymerase chain reaction (qRT-
PCR) assay
Cells of either type were grown or maintained either in serum
containing media (t=0) or in serum-free media for the desired
time period in 100 mm diameter tissue culture Petri dishes.
RNeasy (Qiagen, Valencia, CA) RNA extraction kit was used
throughout. RNA was quantified and its purity assessed by
measurements of OD at 260/280 nm. Reverse-transcription was
performed using the Applied Biosystems (Carlsbad, CA) kit,
according to manufacturer’s instructions. PCR was performed
using TaqMan Assay-on-Demand kit, using the manufacturer’s
sequence-specific primers for each gene and Stratagene Mx3000P
QPCR System. The five putative RUNX3-control genes were
selected at random from the intersection of all putative RUNX3-
control genes (,1,000) and the list of primers reported to be
involved in differentiation and available in the laboratory.
Supporting Information
Supporting Information S1 A novel HMM-based method for
detecting enriched transcription factor binding sites reveals
RUNX3 as a potential target in pancreatic cancer biology.
Calculating the HMM motif entry probability.
Found at: doi:10.1371/journal.pone.0014423.s001 (0.14 MB
DOC)
Figure S1 Changes in ZNF350 mRNA level in PANC-1 cells in
serum-free medium.
Found at: doi:10.1371/journal.pone.0014423.s002 (0.01 MB TIF)
Figure S2 Results from the simulation benchmark. A compar-
ison between DEMON’s and PRIMA’s performance on data sets
with various number of planted motifs.
Found at: doi:10.1371/journal.pone.0014423.s003 (0.32 MB TIF)
Figure S3 Results from the simulation benchmark. A compar-
ison between DEMON’s and PRIMA’s performance on data sets
with various sizes.
Found at: doi:10.1371/journal.pone.0014423.s004 (0.38 MB TIF)
Table S1 The list of 45 genes that were identified as
differentially expressed in 3 or more studies out of a list of 10
studies compiled by Brandt, et al. [2].
Found at: doi:10.1371/journal.pone.0014423.s005 (0.08 MB
DOC)
Table S2 Top 10 TFBSs that were found by PRIMA in the
consensus data set and in the 30 consensus genes that exhibited
increased transcription.
Found at: doi:10.1371/journal.pone.0014423.s006 (0.03 MB
DOC)
Table S3 The list of 30 genes whose expression changed
significantly in one cell type, hIPCs or PANC-1.
Found at: doi:10.1371/journal.pone.0014423.s007 (0.05 MB
DOC)
Table S4 Top 10 TFBSs that were found by DEMON in the
PANC-1 vs. hIPCs data set.
Found at: doi:10.1371/journal.pone.0014423.s008 (0.03 MB
DOC)
Table S5 Top 10 TFBSs that were found by PRIMA in the
PANC-1 vs. hIPCs data set.
Found at: doi:10.1371/journal.pone.0014423.s009 (0.03 MB
DOC)
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